IDA Causes: Pregnancy

Switch to mobile view »

Iron Deficiency Anemia Linked to Pregnancy

Along with menstrual blood loss, pregnancy is one of the most common causes of iron deficiency anemia in women of childbearing age.1 IDA may occur during pregnancy because the volume of blood expands and the woman needs more iron to support her baby's growth.2 Serum ferritin and hemoglobin values fall during pregnancy in some women to levels equating IDA.3 And, according to the CDC, there is a 3-fold increase in anemia from the first through the third trimester.2

Women also use up their bodies' iron stores during pregnancy and lose blood during childbirth, which may cause them to need iron supplements for multiple months after having a baby.4

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

Ferralet® 90 is a prescription iron supplement approved for treating anemias that respond to oral iron therapy. Your doctor may prescribe Ferralet® 90 if you have certain anemias associated with pregnancy, blood loss, or metabolic disease, or if you are recovering from surgery or do not have enough iron in your diet.

Important Safety Information

Ferralet® 90 has not been tested in children. Dosing for elderly patients should begin at the lower end of the dosing range.

Talk to your doctor before taking Ferralet® 90 if you have a known sensitivity to any of its ingredients.

Because some medications may interact with Ferralet® 90, you should tell your doctor about any medications you are taking, including antacids and antibiotics.

Before prescribing iron therapy, your doctor will need to determine the type of anemia you have and identify its underlying causes. You should not take this product if you have been diagnosed with hemolytic anemia or an iron overload disorder such as hemochromatosis or hemosiderosis.

If you have certain forms of anemia associated with vitamin B12 deficiency (i.e. pernicious anemia), the Folic acid contained in Ferralet® 90 is not enough to treat your condition. Doses of more than 0.1 mg Folic acid per day can hide the symptoms of these anemias, so your doctor must rule them out before prescribing this product.

Once you begin iron therapy with Ferralet® 90, take the product 2 hours after meals, and do not exceed the recommended dose.

When taking Ferralet® 90, you may experience temporary side effects such as GI irritation, constipation, diarrhea, nausea, vomiting, and dark stools.

Some patients taking Folic acid have reported allergic reactions. Additionally, Ferralet® 90 contains FD&C Yellow No. 5 (tartrazine), which may cause allergic reactions (including bronchial asthma) in certain susceptible people. Although uncommon, tartrazine sensitivity is often seen in patients who also have aspirin hypersensitivity. Contact your doctor and discontinue use if you develop any unusual symptoms.

Keep this product out of reach of children. Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six. Symptoms of overdose include abdominal pain, metabolic acidosis, decline or absence of urine production, nerve damage, coma, convulsions, death, dehydration, congestion of blood vessels, cirrhosis of the liver, low blood pressure, hypothermia, fatigue, nausea, vomiting, diarrhea, black or tarry stools, vomiting blood, rapid heart rate, high blood sugar, drowsiness, abnormal pale or bluish skin color, lack of energy, seizures, and shock. In case of accidental overdose, call a doctor or poison control center immediately.

To report negative side effects, contact Mission Pharmacal Company at 1-800-298-1087 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  1. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006 May;54(5):824-44.
  2. Recommendations to prevent and control iron deficiency in the United States [Internet]. Centers for Disease Control and Prevention; 1998 Apr 3 [accessed 2008 Apr 9]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00051880.htm.
  3. Milman N, Bergholt T, Byg KE, Eriksen L, Graudal N. Iron status and iron balance during pregnancy. A critical reappraisal of iron supplementation. Acta Obstet Gynecol Scand. 1999 Oct;78(9):749-57.
  4. Chan SM, Nelson EA, Leung SS, Li CY. Postnatal iron status of Hong Kong Chinese women in a longitudinal study of maternal nutrition. European Journal of Clinical Nutrition. 2001 Jul;55(7):538-46.